-

Blackstone Hires Shary Moalemzadeh as a Senior Managing Director for Blackstone Tactical Opportunities

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that it is hiring Shary Moalemzadeh, a seasoned private equity and credit investment professional with almost three decades of experience, as a Senior Managing Director.

Mr. Moalemzadeh will be a senior partner based in New York for Blackstone’s opportunistic investing platform, Blackstone Tactical Opportunities (“Tac Opps”). He will start in April and report to David Blitzer, Global Head of Blackstone Tactical Opportunities.

David Blitzer said: “Shary is a highly talented investor with a wide range of expertise, which perfectly fits Tac Opps’ mission to provide flexible capital solutions across industries, asset classes and geographies. We’re pleased to welcome him to Blackstone as we continue to grow our business and identify new investment opportunities moving forward.”

Shary Moalemzadeh added: “I’m excited to join the Blackstone Tactical Opportunities team. Tac Opps is an innovative business. The scale of their platform and flexibility of their mandate has positioned them exceptionally well to be an investment partner of choice to businesses globally. I look forward to working with them in the years ahead.”

Mr. Moalemzadeh joins Blackstone after spending over 17 years at Carlyle where he was most recently Co-Head of Illiquid Credit Strategies and Co-Head of Carlyle Strategic Partners, its special situation business. Prior to that, Mr. Moalemzadeh was a Principal and founding member of Jacksons LLC, a New York-based private equity firm. Earlier in his career, he worked at Vestar Capital Partners and the Leveraged Finance Group at Merrill Lynch. Mr. Moalemzadeh received a BS in finance and graduated cum laude from New York University’s Stern School of Business.

Blackstone Tactical Opportunities

Tactical Opportunities (Tac Opps) is Blackstone's opportunistic investment platform. The Tac Opps team invests globally across asset classes, industries and geographies, seeking to identify and execute on attractive, differentiated investment opportunities. As part of the strategy, the team leverages the intellectual capital across Blackstone’s various businesses while continuously optimizing its approach in the face of ever-changing market conditions.

Blackstone

Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $619 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contacts

Matt Anderson
212-390-2472
matthew.anderson@blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Matt Anderson
212-390-2472
matthew.anderson@blackstone.com

More News From Blackstone

Blackstone Real Estate Debt Strategies Launches Homebuilder Lending Platform

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that Blackstone Real Estate Debt Strategies (“BREDS”) has launched a lending platform that will provide much needed capital and flexibility to homebuilders, and expects to enable the construction of over 50,000 for-sale homes across the United States annually. This lending platform is supported by BREDS portfolio company, Brio Homebuilder Solutions, as well as partnerships with third parties. This commitment comes at a time when t...

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

NEW YORK & NATICK, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis (“CF”), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagram’s ANG003, a novel orally delivered recombinan...

Anthropic Partners with Blackstone, Hellman & Friedman, and Goldman Sachs to Launch Enterprise AI Services Firm

SAN FRANCISCO--(BUSINESS WIRE)--Anthropic, Blackstone, Hellman & Friedman, and Goldman Sachs today announced the formation of a new AI-native enterprise services firm that will work with companies to rapidly bring Claude into their core business operations. The new firm is a standalone entity with Anthropic engineering and partnership resources embedded directly within its team. Alongside the founding partners, the new company is backed by a consortium of leading alternative asset managers...
Back to Newsroom